 |
|
|
| |
Long-Term Efficacy of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without
Ribavirin in HCV Genotype 1-Infected Patients With or Without Cirrhosis
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Stefan Zeuzem1, Ira M Jacobson2, Jordan J Feld3, Heiner Wedemeyer4, Xavier Forns5, Pietro Andreone6, Massimo G Colombo7, David E Bernstein8, Fred Poordad9, Christophe Hezode10, Thomas Podsadecki11, Wangang Xie11, Tami Pilot-Mati as11, Regis A Vilchez12*, John Vierling13
1JW Goethe University, Frankfurt, Germany; 2Weill Cornell Medical College, New York, New York, United States; 3Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 4Medizinische Hochschule Hannover, Hannover, Germany; 5Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain; 6Diparti mento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy; 7Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 8North Shore University Hospital, Manhasset, New York, United States; 9The Texas Liver Insti tute/University of Texas Health Science Center, San Antonio, Texas, United States; 10Henri Mondor University Hospital, AP-HP, Universite Paris-Est, Creteil, France; 11AbbVie Inc., North Chicago, Illinois, United States; 12Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas,United States; 13Baylor College of Medicine St. Luke's Advanced Liver Therapies, Houston, Texas, United States
|
| |
|
|
|
|
|
